Compare ADMA Biologics Inc (ADMA) vs LyondellBasell Industries NV (LYB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs LyondellBasell Industries NV — how do they compare? ADMA Biologics Inc trades at $9.26 (market cap $2.13B), while LyondellBasell Industries NV trades at $56.03 (market cap $17.62B). The key difference: LyondellBasell Industries NV is far larger — about 8.3× ADMA Biologics Inc's market cap, and LyondellBasell Industries NV pays a 7.55% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | LYB | |
|---|---|---|
Market Cap | $2.13B | $17.62B |
Sector | Health | Basic Materials |
52-Week High | $20.38 | $82.38 |
52-Week Low | $7.60 | $42.28 |
Enterprise Value | $2.20B | $29.24B |
Dividend Yield | — | 7.55% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
LyondellBasell (LYB) trades at $54.61, up 2.33% on the day, with a bearish technical signal but oversold RSI readings. The company reported a net loss of -$745M in 2025 with revenue declining to $30.15B, though it beat EPS estimates in two of the last three quarters. Recent news highlights a packaging collaboration with Mondelez and upcoming Q2 2026 earnings on July 31. Cash flow remains positive with $61M net inflow in 2025, while debt-to-asset ratio increased to 38.18%.
Outlook is mixed: analyst consensus price target of $73.11 suggests 34% upside, supported by cost-cutting and recycling initiatives, but persistent margin pressures and high debt pose risks. Investors should weigh the value opportunity (P/S of 0.57) against earnings volatility and sector headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →
